However, only Sun et al. [42] reported significantly lower MMP-3 levels in RA patients treated with TNFαI, suggesting that serum MMP-3 may be a useful biomarker for monitoring anti-TNF-α treatment efficiency, whereas these levels did not correlate with the disease activity indices of RA. Here, TNF is linked to rheumatoid arthritis.